Allogreffe de cellules souches hématopoïétiques : réalisation et complications. EMC d'hématologie, 2010. ,
Graft-versus-host disease. Lancet. 2 mai, pp.1550-61, 2009. ,
Acute graft-versus-host disease: a bench-to-bedside update, Blood, vol.124, issue.3, pp.363-73, 2014. ,
DOI : 10.1182/blood-2014-01-514786
Activité nationale de greffe de CSH, 2012. ,
Hematopoietic Stem-Cell Transplantation, New England Journal of Medicine, vol.354, issue.17, pp.1813-1839, 2006. ,
DOI : 10.1056/NEJMra052638
URL : https://hal.archives-ouvertes.fr/hal-00849640
Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease, J Am Acad Dermatol. avr, vol.66, issue.4, pp.515-516, 2012. ,
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report, Biology of Blood and Marrow Transplantation, vol.11, issue.12, pp.945-56, 2005. ,
DOI : 10.1016/j.bbmt.2005.09.004
IBMTR Severity INDEX FOR GRADING ACUTE GRAFT-VERSUS-HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE, British Journal of Haematology, vol.97, issue.4, pp.855-64, 1997. ,
DOI : 10.1046/j.1365-2141.1997.1112925.x
Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire, Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 15 août, pp.1495-500, 2005. ,
Acute graft versus host disease, Orphanet Journal of Rare Diseases, vol.2, issue.1, p.35, 2007. ,
DOI : 10.1186/1750-1172-2-35
The biology of graft-versus-host reactions, Harvey Lect, vol.62, pp.21-78, 19671966. ,
Analysis of risk factors for acute cutaneous graft-versus-host disease after allogeneic stem cell transplantation, British Journal of Dermatology, vol.7, issue.6, pp.1129-1163, 2003. ,
DOI : 10.1038/sj.bmt.1701334
Cutaneous Graft-versus-Host Disease: A Guide for the Dermatologist, Dermatology, vol.216, issue.4, pp.287-304, 2008. ,
DOI : 10.1159/000113941
A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment, Blood. 15 oct, vol.76, issue.8, pp.1464-72, 1990. ,
Cutaneous graft-versus-host disease: rationales and treatment options, Dermatologic Therapy, vol.10, issue.2, pp.219-247, 2011. ,
DOI : 10.1111/j.1529-8019.2011.01397.x
Histopathology of graftvs .-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors, Transplant Proc. déc, vol.6, issue.4, pp.367-71, 1974. ,
Value of Skin Biopsies in Assessing Prognosis and Progression of Acute Graft-Versus-Host Disease, The American Journal of Surgical Pathology, vol.21, issue.9, pp.988-96, 1997. ,
DOI : 10.1097/00000478-199709000-00002
Deposition of IgM and complement at the dermoepidermal junction in acute and chronic cutaneous graft-vs-host disease in man, J Immunol Baltim Md, vol.120, issue.5, pp.1485-92, 1950. ,
Immunohistochemistry of Cutaneous Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation, The Journal of Dermatology, vol.60, issue.6, pp.314-337, 1991. ,
DOI : 10.1111/j.1346-8138.1991.tb03091.x
Role of Skin Biopsy to Confirm Suspected Acute Graft-vs-Host Disease, Archives of Dermatology, vol.142, issue.2, pp.175-82, 2006. ,
DOI : 10.1001/archderm.142.2.175
Clinical Significance of Skin Biopsies in the Diagnosis and Management of Graft-vs-Host Disease in Early Postallogeneic Bone Marrow Transplantation, Archives of Dermatology, vol.136, issue.6, pp.717-738, 2000. ,
DOI : 10.1001/archderm.136.6.717
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia, New England Journal of Medicine, vol.314, issue.12, pp.729-764, 1986. ,
DOI : 10.1056/NEJM198603203141201
Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLAidentical sibling bone marrow transplantation, Blood. 1 oct, vol.92, issue.7, pp.2303-2317, 1998. ,
Prophylaxis and treatment of GVHD: EBMT???ELN working group recommendations for a standardized practice, Bone Marrow Transplantation, vol.92, issue.2, pp.168-73, 2014. ,
DOI : 10.1016/j.bbmt.2010.05.011
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease, Blood, vol.110, issue.8, pp.3064-70, 2007. ,
DOI : 10.1182/blood-2007-04-067215
Current and emerging strategies for the prevention of graft-versus-host disease, Nature Reviews Clinical Oncology, vol.118, issue.9, pp.536-583, 2014. ,
DOI : 10.1002/cncr.24198
Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors, Blood. 15 sept, vol.96, issue.6, pp.2062-2070, 2000. ,
A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation, Bone Marrow Transplantation, vol.34, issue.7, pp.621-626, 2004. ,
DOI : 10.1038/sj.bmt.1704647
Matched and Mismatched Allogeneic Stem-Cell Transplantation From Unrelated Donors Using Combined Graft-Versus-Host Disease Prophylaxis Including Rabbit Anti???T Lymphocyte Globulin, Journal of Clinical Oncology, vol.21, issue.3, pp.506-519, 2003. ,
DOI : 10.1200/JCO.2003.03.129
Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO), Blood, vol.98, issue.10, pp.2942-2949, 2001. ,
DOI : 10.1182/blood.V98.10.2942
Diagnosis and management of acute graft-versus-host disease, British Journal of Haematology, vol.50, issue.1, pp.30-45, 2012. ,
DOI : 10.1111/j.1365-2141.2012.09129.x
Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities, Bone Marrow Transplantation, vol.26, issue.9, pp.985-91, 2000. ,
DOI : 10.1038/sj.bmt.1702639
Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome, Blood. 15 févr, vol.75, issue.4, pp.1024-1054, 1990. ,
Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin, Blood, vol.107, issue.10, pp.4177-81, 2006. ,
DOI : 10.1182/blood-2005-12-4851
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes, Blood, vol.113, issue.13, pp.2888-94, 2009. ,
DOI : 10.1182/blood-2008-07-168401
Early treatment of acute graft-versus-host disease with high-or low-dose 6- methylprednisolone: a multicenter randomized trial from the Italian Group for, Bone Marrow Transplantation. Blood. 1 oct, vol.92, issue.7, pp.2288-93, 1998. ,
The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease, Haematologica. mars, vol.91, issue.3, pp.405-413, 2006. ,
Infliximab treatment for steroid-refractory acute graft-versus-host disease, Haematologica. nov, vol.89, issue.11, pp.1352-1361, 2004. ,
A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease, Biology of Blood and Marrow Transplantation, vol.15, issue.12, pp.1555-62, 2009. ,
DOI : 10.1016/j.bbmt.2009.08.003
Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease, Transplantation. 27 déc, vol.72, issue.12, 2001. ,
A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease, International Journal of Hematology, vol.30, issue.Suppl 2, pp.464-70, 2010. ,
DOI : 10.1007/s12185-010-0516-x
Inolimomab in Steroid-Refractory Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis and Comparison with Other Interleukin-2 Receptor Antibodies, Transplantation, vol.80, issue.6, pp.782-790, 2005. ,
DOI : 10.1097/01.TP.0000173995.18826.DE
Encouraging Results with Inolimomab (Anti-IL-2 Receptor) as Treatment for Refractory Acute Graft-versus-Host Disease, Biology of Blood and Marrow Transplantation, vol.12, issue.11, pp.1135-1176, 2006. ,
DOI : 10.1016/j.bbmt.2006.06.010
Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease, British Journal of Haematology, vol.75, issue.4, pp.568-74, 2005. ,
DOI : 10.1046/j.1365-2141.2001.02582.x
Viral infections in acute graft-versus-host disease: A review of diagnostic and therapeutic approaches, Journal of the American Academy of Dermatology, vol.72, issue.4, pp.696-702, 2015. ,
DOI : 10.1016/j.jaad.2014.12.002
Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions, Journal of the American Academy of Dermatology, vol.65, issue.4, pp.726-758, 2011. ,
DOI : 10.1016/j.jaad.2010.07.042
Incidence of Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome in an HIV Cohort, American Journal of Clinical Dermatology, vol.115, issue.9102, pp.49-54, 2012. ,
DOI : 10.2165/11593240-000000000-00000
Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis, J Am Acad Dermatol. août, vol.69, issue.2, pp.173-174, 2013. ,
Toxic epidermal necrolysis, Journal of the American Academy of Dermatology, vol.56, issue.2, pp.181-200, 2007. ,
DOI : 10.1016/j.jaad.2006.04.048
Drug-induced toxic epidermal necrolysis. II. Current aspects, Clinics in Dermatology, vol.11, issue.4, pp.493-500, 1993. ,
DOI : 10.1016/0738-081X(93)90156-7
Nécrolyse épidermique toxique (syndrome de Lyell) Dermatologie et infections sexuellement transmissibles. 5ème édition, Masson ,
Renal involvement in toxic epidermal necrolysis, Journal of the American Academy of Dermatology, vol.34, issue.6, pp.1088-90, 1996. ,
DOI : 10.1016/S0190-9622(96)90297-2
Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study, Intensive Care Medicine, vol.123, issue.12, pp.1237-1281, 1997. ,
DOI : 10.1007/s001340050492
Nécrolyse épidermique toxique (syndromes de Stevens- Johnson et de Lyell) : protocole national de diagnostic et de soin, 2010. ,
Stevens???Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study, Journal of Investigative Dermatology, vol.128, issue.1, pp.35-44, 2008. ,
DOI : 10.1038/sj.jid.5701033
Toxic Epidermal Necrolysis (Lyell Syndrome), Archives of Dermatology, vol.126, issue.1, pp.37-42, 1981. ,
DOI : 10.1001/archderm.1990.01670250043005
ALDEN, an Algorithm for Assessment of Drug Causality in Stevens???Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case???Control Analysis, Clinical Pharmacology & Therapeutics, vol.40, issue.1, pp.60-68, 2010. ,
DOI : 10.1016/0895-4356(96)00035-2
Toxic epidermal necrolysis following morbilli-parotitis-rubella vaccination, Journal of the European Academy of Dermatology and Venereology, vol.12, issue.1, pp.59-61, 1999. ,
DOI : 10.1001/archderm.131.6.669
A Rare Case of Toxic Epidermal Necrolysis with Unexpected Fever Resulting from Dengue Virus, Case Reports in Dermatology, vol.2, issue.3, pp.189-94, 2010. ,
DOI : 10.1159/000322963
Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis., Mediterranean Journal of Hematology and Infectious Diseases, vol.3, issue.1, p.2011004, 2011. ,
DOI : 10.4084/mjhid.2011.004
A case of toxic epidermal necrolysis with involvement of the GI tract after systemic contrast agent application at cardiac catheterization, Gastrointestinal Endoscopy, vol.62, issue.4, pp.638-680, 2005. ,
DOI : 10.1016/j.gie.2005.06.034
Prognostic value of histologic features of toxic epidermal necrolysis, Journal of the American Academy of Dermatology, vol.68, issue.2, pp.29-35, 2013. ,
DOI : 10.1016/j.jaad.2011.10.007
Investigation of Mechanisms in Toxic Epidermal Necrolysis Induced by Carbamazepine, Archives of Dermatology, vol.130, issue.5, pp.598-604, 1994. ,
DOI : 10.1001/archderm.1994.01690050066011
Uncovering Histologic Criteria With Prognostic Significance in Toxic Epidermal Necrolysis, Archives of Dermatology, vol.141, issue.6, pp.683-690, 2005. ,
DOI : 10.1001/archderm.141.6.683
Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells, Journal of Allergy and Clinical Immunology, vol.114, issue.5, pp.1209-1224, 2004. ,
DOI : 10.1016/j.jaci.2004.07.047
The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum, British Journal of Dermatology, vol.6, issue.2, pp.319-343, 2006. ,
DOI : 10.1046/j.1523-1747.2000.00816.x
Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement, Archives of Dermatology, vol.129, issue.4, pp.466-474, 1993. ,
DOI : 10.1001/archderm.129.4.466
Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis, British Journal of Dermatology, vol.86, issue.2, pp.322-352, 2012. ,
DOI : 10.1111/j.1365-2133.2011.10649.x
Immune pathomechanism of drug hypersensitivity reactions, Journal of Allergy and Clinical Immunology, vol.127, issue.3, pp.74-81, 2011. ,
DOI : 10.1016/j.jaci.2010.11.048
Stimulation of human T cells with sulfonamides and sulfonamide metabolites, Journal of Allergy and Clinical Immunology, vol.125, issue.2, pp.411-419, 2010. ,
DOI : 10.1016/j.jaci.2009.10.031
Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis, Nature Medicine, vol.203, issue.12, pp.1343-50, 2008. ,
DOI : 10.1038/nm.1884
Granulysin as a Marker for Early Diagnosis of the Stevens???Johnson Syndrome, Annals of Internal Medicine, vol.151, issue.7, pp.514-519, 2009. ,
DOI : 10.7326/0003-4819-151-7-200910060-00016
Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment, Journal of Allergy and Clinical Immunology, vol.122, issue.5, pp.992-1000, 2008. ,
DOI : 10.1016/j.jaci.2008.06.013
Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin, Science, vol.282, issue.5388, pp.490-493, 1998. ,
DOI : 10.1126/science.282.5388.490
Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome, Dermatol Online J. juin, vol.8, issue.1, p.5, 2002. ,
SCORTEN: a severity-of-illness score for toxic epidermal necrolysis, J Invest Dermatol. août, vol.115, issue.2, pp.149-53, 2000. ,
Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome, Archives of Dermatology, vol.136, issue.3, pp.323-330, 2000. ,
DOI : 10.1001/archderm.136.3.323
Prise en charge de la douleur dans le syndrome de Stevens-Johnson/Lyell et les autres dermatoses bulleuses ??tendues, Annales de Dermatologie et de V??n??r??ologie, vol.138, issue.10, pp.694-701, 2011. ,
DOI : 10.1016/j.annder.2011.05.029
Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis?, Intensive Care Medicine, vol.25, issue.11, pp.1307-1317, 1999. ,
DOI : 10.1007/s001340051063
Toxic Epidermal Necrolysis, Journal of Burn Care & Rehabilitation, vol.18, issue.6, pp.520-524, 1997. ,
DOI : 10.1097/00004630-199711000-00009
Successful dexamethasone pulse therapy in a toxic epidermal necrolysis (TEN) patient featuring recurrent TEN to oxazepam, Clinical and Experimental Dermatology, vol.140, issue.8, pp.654-660, 2001. ,
DOI : 10.1001/archderm.131.6.669
Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis, The Lancet, vol.352, issue.9140, pp.1586-1595, 1998. ,
DOI : 10.1016/S0140-6736(98)02197-7
Toxic Epidermal Necrolysis: Does Immunoglobulin Make a Difference?, Journal of Burn Care & Rehabilitation, vol.25, issue.1, pp.81-89, 2004. ,
DOI : 10.1097/01.BCR.0000105096.93526.27
Communication orale 90: Mortalité du SJS-NET et impact de la ciclosporine: étude rétrospective de 130 patients, Journées Dermatologiques de Paris, 2014. ,
Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment, J Am Acad Dermatol. août, vol.69, issue.2, pp.187-188, 2013. ,
Toxic Epidermal Necrolysis Possibly Linked to Aztreonam in Bone Marrow Transplant Patients, Annals of Pharmacotherapy, vol.101, issue.1, pp.34-39, 1992. ,
DOI : 10.1177/106002809202600109
Toxic epidermal necrolysis: differential diagnosis of an epidermolytic dermopathy in a hematopoietic stem cell transplant recipient, Bone Marrow Transplantation, vol.30, issue.5, pp.331-334, 2002. ,
DOI : 10.1038/sj.bmt.1703624
Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation, Ann Hematol. mai, vol.82, issue.5, pp.303-307, 2003. ,
Toxic epidermal necrolysis after allogeneic haematopoietic stem cell transplantation, Bone Marrow Transplantation, vol.23, issue.4, pp.245-251, 2007. ,
DOI : 10.1038/sj.bmt.1705572
Stage IV cutaneous acute graft-versus-host disease. Clinical and histological study of 15 cases, Journal of the European Academy of Dermatology and Venereology, vol.157, issue.12, pp.1398-404, 2009. ,
DOI : 10.1111/j.1468-3083.2009.03326.x
Toxic epidermal necrolysis after bone marrow transplantation: Study of nine cases, Journal of the American Academy of Dermatology, vol.23, issue.5, pp.870-875, 1990. ,
DOI : 10.1016/0190-9622(90)70307-4
Extensive Toxic Epidermal Necrolysis Versus Acute Graft Versus Host Disease After Allogenic Hematopoietic Stem-Cell Transplantation, Journal of Burn Care & Research, vol.35, issue.6, pp.431-436, 2014. ,
DOI : 10.1097/BCR.0000000000000040
Oral mucositis in cancer treatment: Natural history, prevention and treatment, Mol Clin Oncol. mai, vol.2, issue.3, pp.337-377, 2014. ,
Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin, Science Translational Medicine, vol.2, issue.13, pp.13-15, 2010. ,
DOI : 10.1126/scitranslmed.3000406
Biomarkers for acute GVHD: can we predict the unpredictable?, Bone Marrow Transplantation, vol.11, issue.6, pp.755-60, 2013. ,
DOI : 10.1016/j.exphem.2006.02.013
A biomarker panel for acute graft-versus-host disease, Blood, vol.113, issue.2, pp.273-281, 2009. ,
DOI : 10.1182/blood-2008-07-167098